BioSyent (CVE:RX) Stock Passes Above Fifty Day Moving Average – What’s Next?

BioSyent Inc. (CVE:RX) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$13.63 and traded as high as C$15.78. BioSyent shares last traded at C$15.44, with a volume of 5,327 shares trading hands.

Wall Street Analyst Weigh In

Separately, Bloom Burton upgraded BioSyent from a “moderate buy” rating to a “strong-buy” rating in a research report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

BioSyent Trading Down 1.0%

The company has a debt-to-equity ratio of 2.24, a current ratio of 5.06 and a quick ratio of 6.91. The firm has a market cap of C$174.58 million, a price-to-earnings ratio of 20.72 and a beta of 0.52. The firm’s fifty day moving average is C$13.74 and its 200-day moving average is C$12.34.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.